Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07

The combination of oxaliplatin and fluoropyrimidine for 6 months is one of the standard options for adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs). The optimal duration of oxaliplatin to diminish neurotoxicity without compromising efficacy needs to be clarified. PATIENTS A...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Kim, Sun Young, Lee, Jeeyun, Yun, Seong Hyeon, Kim, Hee Cheol, Lee, Woo Yong, Kim, Tae Won, Hong, Yong Sang, Lim, Seok-Byung, Baek, Ji Yeon, Oh, Jae Hwan, Ahn, Joong Bae, Shin, Sang Joon, Han, Sae-Won, Kim, Seong Geun, Kang, Seok Yun, Sym, Sun Jin, Zang, Dae Young, Kim, Yeul Hong, Choi, In Sil, Kang, Jung Hun, Kim, Min-Ji, Park, Young Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671755/
https://www.ncbi.nlm.nih.gov/pubmed/35772045
http://dx.doi.org/10.1200/JCO.21.02962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671755/
https://www.ncbi.nlm.nih.gov/pubmed/35772045
http://dx.doi.org/10.1200/JCO.21.02962

Ejemplares similares